Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

Muhammad Abdulghani, Ralph A. DeFronzo, Luke Norton

Research output: Contribution to journalReview article

123 Citations (Scopus)

Abstract

Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of antidiabetes drugs, and members of this class are under various stages of clinical development for the management of type 2 diabetes mellitus (T2DM). It is widely accepted that SGLT2 is responsible for >80% of the reabsorption of the renal filtered glucose load. However, maximal doses of SGLT2 inhibitors fail to inhibit >50% of the filtered glucose load. Because the clinical efficacy of this group of drugs is entirely dependent on the amount of glucosuria produced, it is important to understand why SGLT2 inhibitors inhibit <50% of the filtered glucose load. In this Perspective, we provide a novel hypothesis that explains this apparent puzzle and discuss some of the clinical implications inherent in this hypothesis.

Original languageEnglish
Pages (from-to)3324-3328
Number of pages5
JournalDiabetes
Volume62
Issue number10
DOIs
Publication statusPublished - 1 Oct 2013

    Fingerprint

Cite this